NCT01686061

Blepharospasm Patient Survey for Patients With Blepharospasm

Blepharospasm Patient Survey: A Structured Interview Evaluating Previous and Current incobotulinumtoxinA, abobotulinumtoxinA and onabotulinumtoxinA Treatment for Patients With Blepharospasm

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 124 (actual)
• Sponsor: Merz Pharmaceuticals GmbH · Industry
• Sex: All
• Age: 18 Years – 81 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this survey is to collect detailed information on patients treated for blepharospasm with incobotulinumtoxinA, abobotulinumtoxinA and onabotulinumtoxinA, including how often they are treated with botulinum toxin, how long their treatment lasts, how satisfied they are with their treatment, and if there is any improvement in their symptoms with the treatment.

Detailed description

This study is open to males and females \> 18 years and \< 81 years with a clinical diagnosis of blepharospasm.

Conditions

• Blepharospasm

Interventions

Type	Name	Description
OTHER	No intervention- only one time survey

Timeline

• Start date: 2012-09-01
• Primary completion: 2013-04-01
• Completion: 2013-04-01
• First posted: 2012-09-17
• Last updated: 2022-10-28

Locations

5 sites across 1 country: United States